Clínic Barcelona

The induction of the transcription factor KLF2 improves liver cirrhosis and portal hypertension

A study led by researchers from IDIBAPS shows, for the first time, that the induction in the liver of the transcription factor called KLF2 (Kruppel-like factor 2), a protein that promotes the expression of vasoprotective genes, significantly improves liver cirrhosis and portal hypertension. Dr. Jordi Gracia-Sancho, Ramón y Cajal researcher at the IDIBAPS group Liver hemodynamics and portal hypertension: Digestive bleeding secondary to ruptured esophageal varicose veins, and Dr. Jaume Bosch, director of the same team, have led this study published in the Gut journal whose first authorship share Giusi Marrone and Raquel Maeso-Díaz. This research was conducted in collaboration with a team from the Harvard Medical School & Brigham and Women's Hospital.